Global Minimal Residual Disease Testing Market to grow at a CAGR of 10.61% to reach USD 4,514.74 million by 2032, Evaluates DelveInsight

According to DelveInsight's analysis, The rising demand for minimal residual disease (MRD) testing is largely driven by the increasing prevalence of both solid tumors and blood cancers, including leukemia, multiple myeloma, and lymphoma. Technological advancements in molecular diagnostics have greatly improved the sensitivity and precision of MRD detection, enabling earlier and more accurate assessment of treatment response. Additionally, continuous product innovation and launch activities by major industry players are further boosting market expansion. Altogether, these factors are expected to support strong and consistent growth of the MRD testing market from 2025 to 2032.

DelveInsight's "Minimal Residual Disease Testing Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Minimal Residual Disease Testing companies actively working in the market.

To know more about why North America is leading the market growth in the Minimal Residual Disease Testing market, get a snapshot of the report Minimal Residual Disease Testing Market Trends
https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Minimal Residual Disease Testing Overview
Minimal Residual Disease (MRD) testing is a highly sensitive diagnostic method used to detect small numbers of cancer cells that remain in the body after treatment, even when they are not visible through standard tests. It is commonly used in blood cancers like leukemia, lymphoma, and multiple myeloma to assess treatment effectiveness, predict relapse risk, and guide future therapy decisions. MRD testing uses advanced techniques such as flow cytometry, polymerase chain reaction (PCR), or next-generation sequencing (NGS) to identify cancer cells at very low levels, helping clinicians personalize patient care and improve long-term outcomes.

DelveInsight Analysis: The minimal residual disease testing market size was valued at USD 2,031.45 million in 2024 and is projected to grow at a CAGR of 10.61% from 2025 to 2032, reaching approximately USD 4,514.74 million by 2032.

Minimal Residual Disease Testing Market Insights
Geographically, North America is expected to lead the minimal residual disease (MRD) testing market in 2024, supported by multiple growth factors. The region's strong market position is largely attributed to the increasing incidence of solid tumors and hematologic cancers, which is driving the need for more precise diagnostic tools like MRD testing. Moreover, rapid progress in molecular diagnostics, along with continuous product approvals and launches from major industry players, is further accelerating adoption. Together, these factors solidify North America's role as the largest and most influential market for MRD testing globally.

To read more about the latest highlights related to Minimal Residual Disease Testing, get a snapshot of the key highlights entailed in the Minimal Residual Disease Testing Market Insights
https://www.delveinsight.com/report-store/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Minimal Residual Disease Testing Market Report
• In June 2025, QIAGEN expanded its minimal residual disease (MRD) testing portfolio through new strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. These collaborations aim to strengthen QIAGEN's presence in MRD testing for both solid tumors and blood cancers.
• In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two key solutions. The first, Labcorp Plasma Detect, is designed to help assess the risk of disease recurrence in patients with stage III colon cancer. The second, PGDx elioTM plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, aimed at identifying patients who may benefit from targeted therapies.
• In January 2025, Adaptive Biotechnologies Corporation announced a multi-year exclusive strategic commercial collaboration aimed at advancing MRD monitoring for patients with select blood cancers. The partnership combines Adaptive's clonoSEQ® MRD test with NeoGenomics' COMPASS and CHART assessment services, providing clinicians and patients with deeper insights throughout the treatment journey.
• In May 2024, Tempus announced the clinical launch of its minimal residual disease (MRD) test portfolio, which includes the xM test and the xM (NeXT Personal® Dx) test developed by Personalis. These MRD tests are now available to physicians across the U.S. to support early cancer recurrence detection and ongoing residual disease monitoring.
• Thus, owing to such developments in the market, rapid growth will be observed in the Minimal Residual Disease Testing market during the forecast period

Key Players in the Minimal Residual Disease Testing Market
Some of the key market players operating in the Minimal Residual Disease Testing market include- F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

Which MedTech key players in the Minimal Residual Disease Testing market are set to emerge as the trendsetter explore @ Key Minimal Residual Disease Testing Companies
https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Minimal Residual Disease Testing Market Landscape
Moreover, growing product advancements and strategic partnerships are further strengthening the role of PCR in MRD testing. For instance, in April 2023, Bio-Rad Laboratories, Inc., a leading player in clinical diagnostics, expanded MRD research through several collaborations with biotech firms and research institutions, utilizing its QX600TM Droplet DigitalTM PCR System. Such initiatives highlight the continuous innovation in the PCR segment and reinforce its importance in the evolving MRD testing landscape.
Therefore, these developments are expected to accelerate the growth of this segment, contributing significantly to the overall expansion of the global minimal residual disease testing market.

Scope of the Minimal Residual Disease Testing Market Report
• Coverage: Global
• Study Period: 2022-2032
• Minimal Residual Disease Testing Market Segmentation By Test Type: Polymerase Chain Reaction, Flow Cytometry, Next Generation Sequencing, and Others
• Minimal Residual Disease Testing Market Segmentation By Application: Leukemia, Lymphoma, Solid Tumors, and Others
• Minimal Residual Disease Testing Market Segmentation By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, and Research Centers
• Minimal Residual Disease Testing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Minimal Residual Disease Testing Companies: F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Minimal Residual Disease Testing market will grow by 2032? Click to get a snapshot of the Minimal Residual Disease Testing Market Analysis
https://www.delveinsight.com/sample-request/minimal-residual-disease-testing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.